KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Common Equity: 2010-2015

Historic Common Equity for Biocryst Pharmaceuticals (BCRX) over the last 5 years, with Sep 2015 value amounting to $64.0 million.

  • Biocryst Pharmaceuticals' Common Equity fell 23.26% to $64.0 million in Q3 2015 from the same period last year, while for Sep 2015 it was $64.0 million, marking a year-over-year decrease of 23.26%. This contributed to the annual value of $75.6 million for FY2014, which is 6817.14% up from last year.
  • According to the latest figures from Q3 2015, Biocryst Pharmaceuticals' Common Equity is $64.0 million, which was down 15.83% from $76.1 million recorded in Q2 2015.
  • Biocryst Pharmaceuticals' Common Equity's 5-year high stood at $90.1 million during Q2 2014, with a 5-year trough of -$9.0 million in Q2 2013.
  • Over the past 3 years, Biocryst Pharmaceuticals' median Common Equity value was $64.0 million (recorded in 2015), while the average stood at $39.9 million.
  • In the last 5 years, Biocryst Pharmaceuticals' Common Equity tumbled by 157.78% in 2013 and then spiked by 6,817.14% in 2014.
  • Biocryst Pharmaceuticals' Common Equity (Quarterly) stood at $14.8 million in 2011, then tumbled by 103.07% to -$454,000 in 2012, then plummeted by 148.02% to -$1.1 million in 2013, then spiked by 6,817.14% to $75.6 million in 2014, then decreased by 23.26% to $64.0 million in 2015.
  • Its last three reported values are $64.0 million in Q3 2015, $76.1 million for Q2 2015, and $64.4 million during Q1 2015.